Lonza Group AG
LZAGF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$54.46B
Close$
$-151.47
120.4% downside
Current Fair Value
120.4% downsideOvervalued by 120.4% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $54.46 Billion |
|---|---|
| Enterprise Value | $58.29 Billion |
| Annual dividend | $3.19 |
| Dividend yield | 0.79% |
| Earnings per Share | $13.55 |
| Beta | 0.84 |
| Outstanding Shares | 69,844,229 |
Return
| Return on Equity | 7.67% |
|---|---|
| Return on Assets | 3.41% |
| Return on Invested Capital | 18.75% |
Valuation & Multiples
| P/E Ratio | -410.26 |
|---|---|
| PEG | -1059.22 |
| Price to Sales | 4.03 |
| Price to Book Ratio | 6.4 |
| Enterprise Value to Revenue | 4.53 |
| Enterprise Value to EBIT | 22.07 |
| Enterprise Value to Net Income | 93 |
| Total Debt to Enterprise | 0.07 |
| Debt to Equity | 0.53 |
Revenue Sources
No data
Last Earnings Call
Report Date
July 22, 2026
EPS Estimate
$10.59
Consensus analyst estimateRevenue Estimate
$4.19 B
Consensus analyst estimateNext Earnings Call
Expected Date
January 27, 2027
EPS Estimate
$11.27
Consensus analyst estimateRevenue Estimate
$4.52 B
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Lonza Group AG
16,866 employees
CEO: Wolfgang Wienand
Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and int...